Atossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference
Atossa Therapeutics Releases Preliminary Analysis From Phase 2 Trial Of (Z)-endoxifen As Part Of I-SPY 2 Endocrine Optimization Pilot Will Be Subject Of Poster Presentation At Inaugural RISE UP Breast Cancer Conference
atossa therapeutics发布了（Z）-endoxifen的2期试验初步分析，作为I-SPY 2内分泌优化试点的一部分，将成为首届RISE UP乳腺癌大会海报展示的主题
(Z)-endoxifen at 10 mg once daily met the primary endpoint with 19/20 (95%) receiving > 75 % of planned treatment in I-SPY-2 Phase 2 Trial
(Z)-安多辛每日10毫克一次达到主要终点，I-SPY-2第2期试验中有19/20（95%）受试者接受了计划治疗的>75%。
Low dose (Z)-endoxifen was well tolerated and demonstrated promising rapid activity in reducing 3-wk Ki-67 and FTV Biomarkers
低剂量(Z)-安多辛耐受性良好，并且在减少3周Ki-67和FTV生物标志物方面展示出有希望的快速活性。
资讯热榜
更新时间